Trimethylation of histone 3 lysine 27 (H3K27me3) is a critical epigenetic mark for the maintenance of gene silencing. Additional accumulation of DNA methylation in target loci is thought to cooperatively support this epigenetic silencing during tumorigenesis.
Introduction
Epigenetic silencing of tumor suppressor genes is one of common molecular alterations observed during tumorigenesis (1, 2) . Although DNA methylation of promoter CpG islands is a well-known epigenetic mark, post-translational modifications of histone also have been found in cancer cells (3) (4) (5) . Among many types of histone modifications, trimethylation of histone 3 lysine 27 (H3K27me3, a repressive mark) is critical for normal and aberrant differentiation of stem and progenitor cells (6) . This lysine residue is tri-methylated by the histone methyltransferase EZH2, a key component of polycomb repressive complex 2 (PRC2) (7) . The formation of PRC2 further recruits PRC1 to target loci, thereby causing transcription repression of developmental genes, such as homeobox families (8) .
Studies have suggested that polycomb-mediated histone modifications may initiate epigenetic silencing of tumor suppressor genes in cancer cells (3, 4) . Indeed, PRC2 targets marked by the enrichment of H3K27me3 in either embryonic stem cells or cancer-initiating cells are prone to undergo hypermethylation in cancer cells (9) (10) (11) (12) (13) .
Although DNA methyltransferases can be recruited to target loci for de novo methylation through polycomb-mediated H3K27me3 in an experimental model (14) , the mechanism involved in this epigenetic process remains to be clearly defined. Nonetheless, progressive accumulation of DNA methylation in promoter CpG islands, or promoter hypermethylation, may render these loci to undergo long-term silencing. Therefore, the complex interplay between H3K27me3 and promoter hypermethylation is thought to be essential for establishing heritable silencing during neoplastic development.
Interestingly, several studies observed that many hypermethylated CpG islands actually Author Manuscript Published OnlineFirst on January 7, 2011; DOI: 10.1158/0008-5472. contain low levels of H3K27me3 in cancer cells (15, 16) . On the other hand, genetic knock-down of EZH2 did not alter DNA methylation profiles of candidate CpG islands (17) . As increasing evidence suggests that nucleosomes and chromatin modifications construct an indispensable context for DNA methylation (18) , understanding this epigenetic mechanism may shed new insight into long-term control of gene silencing in cancer.
We previously reported that epigenetic silencing of the tumor suppressor gene CST6 is initiated in mammary epithelial cells exposed to tumor stromal fibroblasts (19) . This aberrant microenvironment activates epithelial AKT1 kinase, resulting in the enrichment of H3K27me3 in the CST6 promoter region (19) . AKT1 kinase is a key downstream effector of the phosphoinositide 3-kinase (PI3K) signaling pathway that regulates diverse cellular functions, including growth, proliferation, survival, metabolism, motility, angiogenesis and vesicle trafficking (20, 21) . To determine whether genome-wide reprogramming of H3K27me3 is instructed by PI3K/AKT signaling, we performed chromatin immunoprecipitation combined with next-generation sequencing (ChIP-seq) and expression microarray analysis in an immortalized mammary epithelial cell line with forced expression of AKT1. By integrating ChIP-seq and expression microarray data, we identified 488 down-regulated loci with increased levels of H3K27me3 in transfected cells relative to vehicle control. We then narrowed the loci down to 180 with a high likelihood of epigenetic repression through activated PI3K/AKT signaling in breast cancer cells lines. The status of promoter hypermethylation was assessed in 40 candidate genes suppressed by activated PI3K/AKT signaling. While both H3K27me3 and promoter hypermethylation were present in selected CpG islands, these epigenetic marks could be mutually exclusive in other loci, suggesting that the two mechanisms complement each other for gene silencing. As we demonstrated a link between PI3K/AKT signaling and epigenetic silencing, the use of both PI3K/AKT inhibitors and epigenetic agents can be a novel therapeutic strategy. Indeed, our data showed that these combined treatments synergistically relieve epigenetic silencing of target genes and suppress cancer cell growth. Therefore, the experimental evidence presented in this study has important implications for improving targeted therapies currently used for cancer treatments. Diagenode; Sparta, NJ) was used for the ChIP assay described previously (19 Methylated DNA immunoprecipitation (meDIP)-and ChIP-qPCR. MeDIP assay was conducted by following published protocol (24) . Briefly, genomic DNA was sheared by sonication to a size range of 300 to 1000-bp. DNA fragments were denatured at 95°C for 10 min and then subjected to immunoprecipitation with a mouse monoclonal antibody against 5-methylcytosine (MAb-335MEC-500; Diagenode). ChIP assay for H3K27me3 was performed according to the previous description for ChIP-seq.
Materials and Methods

Breast
Amounts of both input and pull-down DNA were measured by the NanoDrop 3300 those primers (one pair per gene) with best amplification efficiency and specificity for each gene. Serial dilutions of input DNA were subjected to a SYBR-green real-time PCR assay in order to generate a standard curve for each primer pair. Equal amounts of input and pull-down from each sample were also subjected to PCR analysis. Relative quantification of DNA fragments for each locus was determined by plotting PCR Ct (cycle threshold) values on the standard curve. Fold-difference of pull-down over input DNA was calculated to indicate enrichment levels of a locus amplified by PCR. All assays were performed in two biological replicates.
AKT1 transfection and kinase activity assay. Either MyrAKT1 cDNA or pcDNA3 vehicle control were transfected to MCF10A cells as described previously (19) . After MassARRAY analysis. MassARRAY (Seqenom, Inc.) assay was conducted following previous description (19) . Briefly, bisulfite converted genomic DNA was subjected to PCR amplification and consequent amplicons were further analyzed by mass spectrometry for quantification of DNA methylation. because it is a key effector of PI3K/AKT signaling pathway in breast cancer (27, 28) .
MBDCap-seq and identification of differentially methylated regions.
Elevated (3 to 5-fold) levels of AKT1 kinase were observed in MCF10A transfectants relative to vector control cells (Supplementary Fig. S1 ). ChIP-seq and expression microarray were then employed to determine altered profiles of H3K27me3 in AKT1 target genes in transfected versus control cells (Fig. 1A) . A total of 67 million sequencing reads (total 8 lanes, 4 lanes per sample) were generated, with 15.6 and 11.8 million reads mapped to unique genomic locations in transfected and control samples, respectively (Supplementary Fig. S2 and Table S1 ). A ChIP-seq peak calling program, bin-base enrichment thresholds (BELT) algorithm (22) , was used to identify H3K27me3-enriched targets in transfected MCF10A cells relative to control cells (Fig.   1B and Supplementary Tables S1 and S2 ). Consistent with a previously study (29) , H3K27me3 was mostly enriched in gene desert (33%) and intragenic regions (30%) (Fig. 1C) . While it is unclear how over-expressed AKT1 altered H3K27me3 profiles in these genomic regions, we observed enrichments in and around the 5´ transcription start sites of 1493 protein-coding genes in transfected MCF10A cells. Depletion of H3K27me3 was also seen in 1155 genes while the levels remained nearly the same for other 633 genes in both AKT1-transfected and control cells (data not shown). 
results, we found that 488 down-regulated gene loci had higher enrichments of H3K27me3 in transfected MCF10A relative to control cells ( Fig. 1D and E; Supplementary Table S3 ). Pathway analysis revealed that one third (n= 172) of these genes were associated with tumorigenic functions, while the other two sets exhibiting only H3K27me3 (n=1005) or AKT1-downregulation (n= 723) had significantly lower numbers of cancer-related genes ( Fig. 1D and Supplementary Fig. S3 and Table S3 , S4, and S5). In addition, 23% (n=113) of the 488 loci could be PRC targets in stem cells based on previous findings (Supplementary Table S3 ) (30, 31) .
Because the silencing of these 488 loci was experimentally induced in AKT1-transfected breast epithelial cells, we determined whether this down-regulation could genuinely be observed in breast cancer cell lines. A step-wise approach was taken to narrow down a candidate list of epigenetically silenced loci ( Fig. 2A) . First, in silico analysis was conducted using a published microarray dataset of 21 breast cancer cell lines displaying higher kinase AKT1 activities ( 
CpG island regions associated with these genes (Supplementary Fig. S4 ). Levels of H3K27me3 and DNA methylation are summarized in box plots for individual genes in 21 breast cancer cell lines examined (Fig. 3A) . Complex distribution patterns of H3K27me3 and DNA methylation were found in these PI3K/AKT-repressed loci: 13 (group a) displayed both epigenetic marks, 6 (group b) predominantly for H3K27me3, and 7 (group c) for DNA methylation. However, fourteen (35%, group d) of these 40 loci had barely detectable epigenetic marks in these cancer cell lines. From this initial analysis, it is evident that differential patterns of epigenetic marks are present in subsets of these target genes in these cancer cell lines. We additionally examined distribution patterns of these two repressive marks in individual breast cancer cell lines. Levels of H3K27me3 and DNA methylation in 26 loci (groups a-c) that show detectable epigenetic marks are summarized in heatmaps (Fig. 3B) . We found that these cell lines exhibited To validate DNA methylation measured by meDIP-qPCR, we additionally conducted MassARRAY analysis on four genes (SFRP1, HOXA5, HOXA9 , and SYNE2) in the same samples used in Fig. 3 . Both quantitative methods were comparable for differentiating DNA methylation levels among multiple samples (Fig. 4 Supplementary Fig. S5 ). The strongest correlation was found in SYNE2 where the same CpG island region was assayed by both meDIP-qPCR and MassARRAY ( Supplementary Fig. S5 ).
Combined epigenetic and PI3K/AKT-targeted therapies relieve gene silencing and suppress tumor growth. As both PI3K/AKT signaling and epigenetic silencing represent important aspects of cancer development, therapies targeted on these components were previously investigated (32, 33) . Because our data showed a link between activated PI3K/AKT signaling and epigenetic silencing, we treated breast cancer cell lines (n=10) individually with different combinations of 5-aza-2′-deoxycytidine (DAC, 1 μM, DNA demethylating agent), trichostatin A (TSA, 0.2 μM, histone deacetylase inhibitor), and/or LY294002 (5 μM, PI3K/AKT inhibitor) based on previously reported doses (Fig. 5A) (16, 34) . Gene expressions assessed by quantitative reverse transcription (RT)-qPCR, are summarized in box plots (Fig. 5B) . Increased levels of gene expression were consistently found in all treatment groups relative to control (DMSO) groups. Among these, the triple treatment combining both epigenetic drugs (DAC and TSA) and LY294002 dramatically relieved the silencing of these loci in almost all cancer cell lines examined (Fig. 5C ).
The epigenomic changes in T-47D cancer cell line after drug treatments were further investigated through methyl-CpG binding domain-based capture coupled with massively parallel sequencing (MBDCap-seq). The reason for choosing MBDCap-seq is because this method was shown to be more sensitive to enrich CG-rich regions than the meDIP assay in genome-wide studies (25) . As shown in Table S15 ).
Although only one (i.e., ARAP2) of these genes was found in the early list of 180 genes shown in Fig. 2 ., a moderate loss of DNA methylation at those original loci was also found following the treatment of DAC and LY294002 (Supplementary Fig. S6 ).
To determine treatment effects on growth suppression, T-47D cells were treated with DAC and/or LY294002 for a colony-forming assay (Fig. 6A) . To further confirm antitumor effect in vivo, T-47D cells were inoculated into NOD SCID mice and followed by drug treatments (Fig. 6B and C) . Both in vitro and in vivo experiments demonstrated that the combined treatment synergistically reduced the growth and survival of cancer cells while single treatments were less effective on this suppression. Taken together, these studies promisingly demonstrate the feasibility of combining both PI3K/AKTtargeted and epigenetic drugs for future cancer treatments.
Discussion
Recent efforts have been undertaken to identify trans-regulatory factors that trigger epigenetic silencing in cancer cells. Deregulated signaling related to TGF-β and estrogen has been implicated in this initiation process during the differentiation of breast progenitor cells (35) (36) (37) (38) (39) . In this study, we suggest that activated PI3K/AKT signaling is also a trigger of epigenetic silencing. This oncogenic signaling was previously found to be activated in mammary epithelial cells chronically exposed to inflammatory microenvironments and could induce epigenetic silencing of a tumor suppressor gene, (19) . We further demonstrate that activation of this oncogenic signaling In analogous to embryonic stem cells, differentiation-control genes in breast progenitor cells also possess a "bivalent" feature, consisting of an active mark, H3K4me2, and a repressive mark, H3K27me3 (5). Co-existence of these histone marks is to maintain progenitor cells in a "ready state" for lineage-specific development (12) .
CST6, in vitro
In terminally differentiated cells, the bivalent loci retain either activating or repressive marks that are essential to specify specific lineage functions. This epigenetic programming, however, can be redirected by oncogenic signaling (38, 39) .
Interestingly, as demonstrated in this study, we uncovered that activated PI3K/AKT signaling can drive a subset of downstream loci to undergo epigenetic silencing in breast epithelial cells. Indeed, 28% (n=138) of the 488 genes identified through the integrative screening of ChIP-seq and expression microarray data encode putative cellular functions required for normal differentiation ( Supplementary Fig S3 and Table   S3 ). In our experimental model, these genes become transcriptionally silenced and display the repressive H3K27me3 mark in breast epithelial cells.
One of interesting findings in our study is that many of loci loss H3K27me3 but gain DNA methylation in cancer cells. These data seem to support the occurrence of an epigenetic switch between H3K27me3 mark and DNA methylation during tumor progression (15, 16) . This mutually exclusive silencing pattern also indicates that both repressive marks actually have an independent role in the maintenance of gene Meanwhile, our preliminary data indicate that PI3K inhibitor LY294002 can dramatically decrease levels of DNA methyltransferase 3 in multiple breast cancer lines (data not shown). Another study has also suggested that activated PI3K/AKT signaling greatly stabilizes DNA methyltransferase 1 (DNMT1) by attenuating the ubiquitin-proteosome reaction in cancer cells (41) . It is also worthy of note that one recent study demonstrated that estrogen receptor signaling can regulate methylation of H3K27 through the PI3K/AKT pathway (42) .
While more than 20 PI3K-targeted inhibitors have recently been introduced in clinical trials, more work still needs to be done to improve treatment effectiveness in patients (32, 43, 44) . One new strategy is to combine these inhibitors with epigenetic drugs, which have also been used as single agents for myelodysplastic syndrome and other malignancies (45, 46) . As we demonstrated in this study, these combined approaches show promising results in breast cancer treatment. Furthermore, these combined agents can be administered in low-dose ranges (i.e., nanomolar concentrations), which are capable of evoking long-term reactivation of tumor suppressor genes and promote cellular reprogramming. Emerging evidence has shown that this low-dose treatment strategy is sufficient to suppress hematopoietic malignancies and at the same time avoids cytotoxicity (47, 48) . Although this low-dose treatment was not used in this study, our future work will focus on identifying optimal doses in nanomolar concentrations that will not result in acute cytotoxic effects but rather induce sustained anti-tumor responses in vitro and in xenograft models.
Whereas PI3K/AKT signaling is well known to contribute multi-oncogenic functions, our present study has uncovered its unique role in epigenetic silencing. These data also support the notion that polycomb-and DNA hypermethylation-based mechanisms can compensate each other for the maintenance of gene silencing under different genetic backgrounds. As oncogenic signaling cascades can perturb epigenetic balance in cancer genomes, our experimental evidence therefore provides support for combinatorial PI3K/AKT-targeted and epigenetic therapies in future cancer treatment.
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